Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.

摘要: Nine patients with progressive, metastatic disease from primary carcinoma of the colon were entered into a phase I/II study using continuous intravenous infusions granulocyte-macrophage colony-stimulating factor (GM-CSF) and high dose melphalan (120 mg m-2). GM-CSF was given alone to six during first part determine that would produce peripheral leucocyte count (WCC) greater than or equal 50 X 10(9) 1(-1) initially at 3 micrograms kg-1 day-1 escalated 10 after days. The infusion discontinued when WCC exceeded gap one week, over 30 min. recommenced 8 h later continued until neutrophil had 0.5 for 1 week. One patient achieved day-1, but other five who this required escalation kg-1. No toxicity attributed seen. After melphalan, median times severe neutropenia (less 1(-1] thrombocytopenia (greater 20 6 9 days respectively. durations 14 All intensive support duration inpatient stay 24 There treatment related death due renal failure. complete two partial remissions (33% response rate) seen these short (median weeks). This demonstrates by produces significant increments granulocyte counts is not associated any toxicity. induced high-dose appears be reduced subsequent administration which are least as have been reported in historical series used autologous bone marrow rescue.